尿路基因制药
URGN
34.56
-2.05
-5.60%
尿路基因制药
US · URGN
#2773 按市值排名
上市于 2017
34.56
-2.05
-5.60%
实时 - 追踪5344个代码 - 心跳于286秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了1.2个百分点。
机构持股
- 机构持股比例
- 96.01% -1.20pp
- 机构数量
- 225 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Hedge Fund32.05%
Mutual Fund29.70%
Public Company19.53%
VC/PE Fund9.19%
Private Company4.42%
Individual/Insider1.90%
Government Pension Fund1.08%
Other2.09%
主要股东 截至 2026-06-30
RTW Investments, LP
9.30% · 4.54M 股
The Toronto-Dominion Bank
6.90% · 3.37M 股
BlackRock
6.55% · 3.20M 股
Morgan Stanley
5.24% · 2.56M 股
Kynam Capital Management, LP
4.98% · 2.43M 股
Jefferies Financial Group Inc.
4.50% · 2.20M 股
SG Americas Securities, LLC
4.20% · 2.05M 股
American Century Investment Management
3.45% · 1.69M 股
Acorn Bioventures
3.42% · 1.67M 股
Point72 Asset Management, L.P.
3.12% · 1.53M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Arie Belldegrun | Independent Chairperson | 0.84% |
| Elizabeth Barrett | Chief Executive Officer | 0.67% |
| Mark Schoenberg | Chief Medical Officer | 0.12% |
| Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | 0.11% |
| Dong Kim | Chief Financial Officer | 0.09% |
| Fred Cohen | Independent Director | 0.03% |
| James Robinson | Director | 0.02% |
| Christopher Degnan | Chief Financial Officer | 0.00% |
| Daniel Wildman | Independent Director | 0.00% |
| Cynthia Butitta | Independent Director | 0.00% |
| Leana Wen | Independent Director | 0.00% |
| Stuart Holden | Independent Director | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Sale | -871 | $42.92 |
| 2026-09-07 | Mark Schoenberg | Chief Medical Officer | Intent to Sell (Form 144) | -871 | $44.09 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Sale | -1,519 | $42.54 |
| 2026-09-07 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Intent to Sell (Form 144) | -1,519 | $44.09 |
| 2026-09-06 | Mark Schoenberg | Chief Medical Officer | Derivative Exercise and Retained | +796 | -- |
| 2026-09-06 | Jason Smith | General Counsel, Chief Compliance Officer & Corporate Secretary | Derivative Exercise and Retained | +1,815 | -- |
| 2026-08-25 | James Robinson | Director | Derivative Exercise and Retained | +2,000 | -- |
| 2026-08-19 | Mark Schoenberg | Chief Medical Officer | Open Market Disposition | -60,677 | $47.05 |
| 2026-07-08 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $40.00 |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Cynthia Butitta | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Stuart Holden | Independent Director | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Arie Belldegrun | Independent Chairperson | Other Derivative Acquisition | +20,000 | $34.99 |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Daniel Wildman | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Mark Schoenberg | Chief Medical Officer | Automatic Disposition | -10,000 | $35.01 |
| 2026-06-21 | James Robinson | Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | James Robinson | Director | Other Derivative Acquisition | +10,000 | $34.99 |
| 2026-06-21 | Leana Wen | Independent Director | Other Derivative Acquisition | +8,000 | -- |
| 2026-06-21 | Leana Wen | Independent Director | Other Derivative Acquisition | +10,000 | $34.99 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:30 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
尿路基因制药 讨论区 0 条评论